NVO: HIMS Deal and FDA Heat Reshape the Bull Case

Novo Nordisk's deal with Hims & Hers marks a strategic pivot. Rather than fighting the compounding pharmacy ecosystem that grew up around GLP-1 shortages, Novo is co-opting the largest player in that space. HIMS generated $2.35 billion in 2025 revenue with 2.5 million subscribers paying an average of $83 per month — that's a proven customer acquisition machine for exactly the demographic Novo needs.

The logic is straightforward: patients currently using compounded semaglutide through Hims transition to branded Wegovy and Ozempic. Novo gets volume. HIMS gets a legitimate pharmaceutical partnership that resolves its legal exposure from selling compounded versions.

But there's a catch. The economics of telehealth distribution almost certainly involve lower net pricing than Novo's traditional pharmacy channel. With Novo already guiding for 5-13% revenue decline in 2026 due to the 50% price cuts, adding a high-volume, lower-margin distribution channel could accelerate the revenue compression even as it stabilizes unit demand.

The bull case is that volume eventually overwhelms the pricing headwind. If HIMS converts even 500,000 of its subscribers to branded GLP-1s, that's meaningful incremental demand at a time when the market is pricing Novo for decline. The bear case is that Novo is chasing volume at the expense of pricing power — a pharma company's most valuable asset.

The FDA's March 11 warning letter isn't a routine compliance notice. Describing "serious violations" and "systemic failures" in safety reporting — including unreported deaths and strokes connected to Ozempic — this represents the agency's third formal action against Novo's pharmacovigilance practices.

For a company whose entire business depends on two drugs (Ozempic for diabetes, Wegovy for obesity), regulatory friction at this level is material. The immediate risk isn't a product recall — Ozempic and Wegovy remain on the market — but rather the compounding effect on three fronts.

First, any FDA enforcement action adds ammunition to the ongoing Pomerantz investor investigation and potential class action litigation. Securities lawyers don't investigate companies that are doing well. Second, it creates a headwind for the Medicare coverage expansion that bulls were counting on as a volume catalyst. Politicians already skeptical of GLP-1 drug costs now have a safety narrative to lean on. Third, it undermines Novo's ability to push back against further price regulation.

The stock barely moved on the news, which suggests either the market has already priced in maximum regulatory pessimism or investors haven't fully digested the implications. Given the stock's 53% decline from highs, there's a reasonable argument for the former.

At $38.74, Novo Nordisk trades at a trailing P/E of 10.82 on TTM EPS of $3.58. The price sits 24% below the 50-day moving average of $50.78 and 31% below the 200-day average of $56.19. The year low of $35.85 — just 7.5% below the current price — was set recently, suggesting the bottom-fishing hasn't found a floor yet.

The Graham Number — a conservative intrinsic value estimate based on earnings and book value — calculates to roughly $77 per ADR share, more than double the current price. Price-to-book sits at 7.45x, down from double digits during the growth era. The PEG ratio of 0.39 signals the market is deeply discounting future growth.

But the market isn't wrong about everything. Q4 2025 showed negative free cash flow of -$2.43 per share as capital expenditure surged to support manufacturing expansion. The current ratio is 0.80 — below 1.0, meaning current liabilities exceed current assets. Debt-to-equity at 0.67 is manageable but rising. Novo is spending heavily on the future while the present deteriorates.

Q4 2025 revenue of DKK 78.4 billion ($11.2 billion) was the strongest quarter of the year, with gross margins recovering to 80.9% after dipping to 76.1% in Q3. Full-year revenue totaled DKK 308.4 billion across the four quarters.

The EPS trajectory tells the real story. After a strong Q1 at DKK 6.54, earnings deteriorated through mid-year before recovering to DKK 6.06 in Q4. The Q3 trough at DKK 4.50 coincided with the initial CagriSema clinical trial disappointment and early pricing pressure.

Operating income for Q4 was DKK 31.6 billion, a respectable 40.3% margin. But operating cash flow collapsed to DKK 7.6 billion from DKK 46.1 billion in Q3 — a 83% sequential decline driven by massive capex of DKK 18.4 billion for GLP-1 manufacturing expansion. This is the tension at the heart of the NVO thesis: the company is investing aggressively for a future where it may not command premium pricing.

R&D spending hit DKK 14.6 billion in Q4 (18.7% of revenue), the highest ratio of the year. Much of this is directed at oral semaglutide formulations and next-generation obesity compounds — the pipeline that needs to deliver if Novo is to maintain its GLP-1 co-leadership alongside Eli Lilly.